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1 Equal contribution to this work.We wanted to analyze the basis for the distinction between OX1 and OX2 orexin receptors by the
known agonists, orexin-A, orexin-B and Ala11, D-Leu15-orexin-B, of which the latter two show some
selectivity for OX2. For this, chimaeric OX1/OX2 and OX2/OX1 orexin receptors were generated. The
receptors were transiently expressed in HEK-293 cells, and potencies of the agonists to elicit cyto-
solic Ca2+ elevation were measured. The results show that the N-terminal regions of the receptor
are most important, and the exchange of the area from the C-terminal part of the transmembrane
helix 2 to the transmembrane helix 4 is enough to lead to an almost total change of the receptor’s
ligand proﬁle.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The native orexin peptides, orexin-A and -B, are neuropeptides,
which act via two G-protein-coupled receptors, OX1 and OX2 [1,2].
Orexins and orexin receptors took a central position in the sleep
regulation soon after their identiﬁcation and cloning [3–5], but also
other functions have been shown, including regulation of appetite,
stress response and addiction [6–8]. Most interest, from the phar-
macological point of view, probably lies in the development of
orexin receptor antagonists as hypnotics, and possibly agonists as
research tools and drugs for hypersomnia and narcolepsy. Despite
rather intensive drug development approaches from several com-
panies [9], very little is known about the receptor and ligand epi-
topes determining the interactions. Some mutagenesis studieschemical Societies. Published by E
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ell Biology, Department of
ity of Helsinki, Finland. Fax:
kkonen).have been performed with the orexin peptides. The earlier studies
applied mainly truncation and alanine scan [10–12]. These studies
show that the activity is gradually lost during the N-terminal trun-
cation of the peptide, while the C-terminus is unconditionally re-
quired. One interesting ﬁnding emerging from these studies is
that it seems that each mutation affects the OX2 receptors less than
OX1. Since the OX2 receptor does not distinguish between orexin-A
and orexin-B, unlike the OX1 receptor, it would be tempting to sug-
gest that the OX2-like phenotype is something the receptor–
peptide interaction is prone to relax to. However, a later peptide
mutagenesis study suggested that one of the agonist peptides,
Ala11, D-Leu15-orexin-B (A11,DL15-orexin-B), would display signiﬁ-
cant OX2 receptor-selectivity [13]. In a recent study, we show that
indeed this peptide shows selectivity for the OX2 receptor, but
much weaker than originally reported and variable with respect
to different expression systems [14].
Even less is known about the orexin receptor structure. A few
natural mutants are known. The frame-shifting (and thus truncat-
ing) ones of the OX2 receptor, found in narcoleptic canines, are
completely non-functional [4,15]. In contrast, a point mutation
Glu54Lys of OX2, also found in dog, shows proper membrane local-
ization but a strongly reduced orexin-A binding and orexin-A and -
B signaling [15]. Interestingly, this glutamate (and several other
amino acids in its vicinity) is conserved also in OX1 receptorlsevier B.V. All rights reserved.
J. Putula et al. / FEBS Letters 585 (2011) 1368–1374 1369(Glu46). A number of single nucleotide polymorphisms of orexin
receptors are known [6], but have not been consequently investi-
gated. No mutagenesis studies, except for a recent point mutation
study [16], have been performed. In this study, several amino acids
predicted to contribute to antagonist binding were mutated to ala-
nine. Many of the mutations caused dramatic reduction in the
antagonist binding [16].
Orexin receptor subtypes exhibit rather high overall identity
and similarity, yet they show distinct pharmacological proﬁle
towards the agonists orexin-A, orexin-B and A11,DL15-orexin-B,
and a number of subtype selective antagonists have been devel-
oped [9]. Therefore, comparison and exchange of the sequences
motifs should allow identiﬁcation of the sequences important for
selective action of native and synthetic ligands. This approach
was in the current study realized by a series of orexin receptor
chimaeras.
2. Materials and methods
2.1. Drugs and other materials
Human orexin-A, orexin-B and A11,DL15-orexin-B were from
NeoMPS (Strasbourg, France) and the restriction enzymes and
polymerases from Finnzymes (Espoo, Finland), Fermentas GmbH
(St. Leon-Rot, Germany) and New England Biolabs (Ipswich, MA,
USA).
2.2. Cell culture
HEK-293 cells were cultured in high glucose Dulbecco’s Modi-
ﬁed Eagle Medium (DMEM; Gibco, Paisley, UK) with supplements
and otherwise as described in [14]. For Ca2+ experiments, the cells
were cultured on polyethyleneimine-pretreated (25 lg/ml, 1 h,
37 C; Sigma) 96-well polystyrene plates (Greiner). The cells were
transiently transfected utilizing Fugene HD (Roche Diagnostics
GmbH, Mannheim, Germany) – as described in [14] – to introduce
different orexin receptor constructs.
2.3. Construction of orexin receptor vectors
Human OX1 and OX2 cDNAs used here for cloning are the same
as in, e.g. [14]; please also see S3. Cloning was, in part, designed
and simulated with the help of Serial Cloner 1.3 (http://www.
serialbasics.free.fr/Serial_Cloner.html). In the ﬁrst round of muta-
genesis, we constructed two-component chimaeras with the front
part (50-end of the receptor DNA, N-terminus of the receptor pro-
tein) from OX1 and the rear part (30-end of the receptor DNA, C-ter-
minus of the receptor protein) from OX2 (chimaeric orexin
receptors (Ch1–3)) and vice versa (Ch3–6) (Fig. 2, S1 and S2). No
amino acid changes were introduced in the receptors. The stop co-
don (TGA or TAG) was mutated to GGA in all the constructs to al-
low fusion of the receptor with C-terminal green ﬂuorescent
protein (GFP) – and examination of the expression of the mutant
proteins – when cloned into the pEGFP-N3 vector (Clontech, Palo
Alto, CA, USA). The receptors were combined from PCR fragments
in pEGFP-N3 (S1 and S2). All the PCR products and the ﬁnal recep-
tors were sequenced. OX1-GFP was ‘‘reconstructed’’ from Ch2 and
Ch4 by exchanging the front part of Ch4 with the front part of
Ch2 (HindIII–BstxI-cut). OX2-GFP was ‘‘reconstructed’’ from Ch1
and Ch5 by exchanging the front part of Ch1 with the front part
of Ch5 (HindIII–BstxI-cut). The second round of mutagenesis (Ch7
and Ch8; Fig. 2, S2) was performed without PCR utilizing the native
restriction sites for BstxI and MscI. For Ch7, Ch1 was cut with BstxI
and BamHI and the 770 bp excised fragment replaced with the cor-
responding 740 bp fragment from Ch5. For construction of Ch8, the
entire Ch2 and Ch4 had to be transferred to pUC18 plasmid (withenzymes HindIII and BamHI), since the backbone of pEGFP-N3 con-
tains restriction sites for MscI. pUC18-Ch4 was cut with MscI and
BamHI and the 170 and 580 bp excised fragments replaced with
the corresponding 790 bp fragment from Ch2. Finally, Ch8 was
transferred back to pEGP-N3 with HindIII and BamHI. DNA and
protein sequences of all the constructs are presented in the Supple-
mentary data (S3 and S4, respectively). Following abbreviations are
used in context with the orexin receptor peptide sequences: C-ter-
minus of orexin receptors (C); extracellular loops 1–3 of orexin
receptor (EC1–3); intracellular loops 1–3 of orexin receptor (IC1–
3); N-terminus of orexin receptors (N); transmembrane helices
1–7 of orexin receptor (TM1–7).
2.4. Ca2+ measurements
Calcium measurements were performed at 37 C using FlexSta-
tion ﬂuorescence plate reader (Molecular Devices, Sunnyvale, CA,
USA) with cells loaded ﬂuo-4 acetoxymethyl ester (Molecular
Probes/Invitrogen) as described in [14]. The data were analyzed
in Microsoft Excel [14]. The results are presented as mean ± S.E.
Each construct was measured in quadruplicate in 4–13 separate
transfections.
2.5. Data analysis
Student’s two-tailed t-test with Bonferroni correction was used
in all statistical comparisons. Microsoft Excel was used for the non-
linear curve-ﬁtting used for the determination of the pEC50 values.
The signiﬁcances are as follows: ns (not signiﬁcant); ⁄P < 0.05;
⁄⁄P < 0.01; ⁄⁄⁄P < 0.001. The symbol ‘‘’’ is used for the second com-
parison (NS stands for not signiﬁcant) and ‘‘’’ for the third (NS
stands for not signiﬁcant).3. Results and discussion
We have previously expressed wild-type GFP-tagged OX1 and
OX2 orexin receptors in HEK-293 cells receptors [14]; as already
conﬁrmed in that study, the pharmacology of the receptors was
very much as expected from previous studies (see e.g. [2]) with
respect to the endogenous ligands orexin-A and orexin-B, i.e. the
ligands were approximately equipotent on the OX2 receptor
(orexin-B 1.6-fold more potent) (Fig. 3B–D), whereas orexin-A
was clearly more potent (5.5-fold) on the OX1 receptor (Fig. 3A,
C, and D). The putative OX2-selective ligand, A11,DL15-orexin-B,
was also clearly more potent on the OX2 receptors than on the
OX1 receptors (Fig. 3). Thus, OX1 and OX2 receptors display distinct
agonist potency proﬁles (orexin-A > orexin-B A11,DL15-orexin-B
and orexin-BP orexin-A > A11,DL15-orexin-B, respectively).
In the ﬁrst round of mutagenesis, we replaced the OX2 receptor
subtype sequence with the OX1 sequence from N-terminus to
C-terminus in three steps and vice versa, i.e. approximately at the
1/4 (N–TM2; Ch1, Ch4), 1/2 (N–TM4; Ch2, Ch5) and 3/4 of the
length (N–TM6; Ch3, Ch6) (Figs. 1 and 2, S2). In Ca2+ experiments,
the subtype-non-selective agonist, orexin-A, did not show signiﬁ-
cant difference in potency between OX1 and OX2. Among the other
clones, marked differences in the potency of orexin-A were seen
(pEC50 between 8.15 and 6.37; Fig. 4A).
Differential expression (or signal coupling) would cause prob-
lems in the analysis of the absolute agonist potencies. Luckily,
the proﬁle of the three agonists could be followed instead of abso-
lute potencies, due to the ‘‘internal control’’ offered by the non-
selective agonist orexin-A. The exchange of the N- or C-terminal
quarter (N–TM2 or TM6–C, respectively) did not change the proﬁle
of the receptor, i.e. Ch1 and Ch6 are similar to OX2 and Ch3 and Ch4
similar to OX1 (Figs. 2 and 4). A dramatic effect on the receptor
Fig. 1. Representation of the cut-points for the construction of the chimaeric orexin receptors in snake-like plots of OX1 and OX2 receptor. There are signiﬁcant stretches of
complete amino acid identity in the transition zones, and therefore, similar to this ﬁgure, the exact point of transition from one subtype to another cannot be pointed out, but
is represented by the gray boxes numbered 1–3.
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was exchanged. Ch2, with the N-terminal half from OX1 and
the C-terminal from OX2 (Fig. 2), effectively adopted a proﬁle of
OX1 receptors, though with somewhat increased potency of
A11,DL15-orexin-B (Fig. 4). Similarly, the proﬁle of Ch5, with the
N-terminal half from OX2 (N–TM4) and the C-terminal (TM4–C)from OX1 (Fig. 2), is essentially indistinguishable from that of
OX2 (Fig. 4).
The data from the ﬁrst round of mutagenesis thus indicates that
the most important part for the agonist-selectivity lies in the 2nd
quarter of the receptors (TM2–TM4); since there is high homology
in this area between the receptor subtypes, the area with sequence
Fig. 2. Representation of the design of each chimaeric orexin receptor in snake-like plots. OX1 sequence is marked in light gray and OX2 in black. Similar to Fig. 1, there are full
sequence homologies in each stretch where the exchange was made and therefore the exact point of transition cannot be pointed out; these areas are marked in darker gray.
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the C-terminal part of TM4 (Figs. 1 and 2). We therefore con-
structed two additional chimaeric receptors, Ch7 and Ch8, where
only this part (the sequence between the ‘‘cut-point areas’’ 1 and
2 of Fig. 1) was exchanged (Fig. 2). Indeed, Ch7 with most of the se-
quence from the OX1 receptor and TM2–TM4 from OX2 (Fig. 2),
adopted a proﬁle very similar to OX2 with only slightly lower po-
tency of A11,DL15-orexin-B (Fig. 4). Ch8 with most of the sequence
from the OX2 receptor and TM2–TM4 from OX1 (Fig. 2), changed
it proﬁle to one much more like OX1 than OX2, but it still retained
higher relative potencies of both orexin-B and A11,DL15-orexin-B
than OX1 (Fig. 4). However, the overall functionality of Ch8 is ques-tionable; very low overall GFP ﬂuorescence (i.e. receptor expres-
sion level) was observed (not shown), which also is likely
reﬂected in the low potency of orexin-A.
The mutagenesis thus identiﬁes the area spanning from TM2 to
TM4 as almost the sole determinant of agonist selectivity. This area
comprises the C-terminal part of TM2, EC1, TM3, IC2 and most of
TM4 of the receptor. However, also other parts of the receptor
seem to act in concert with these parts, and thus the complete li-
gand proﬁle is likely determined by the receptor as an entity. In
comparison of all the chimaeras (Fig. 4), it seems that a fully
OX1-like proﬁle cannot be obtained with any of the chimaeras, of
which even the closest ones (Ch2, Ch3 and Ch4) show a somewhat
Fig. 3. Concentration–response relationships for the orexin peptides on native orexin receptors. (A and B) The average concentration–response curves from 4 batches of cells.
(C) The averaged pEC50 values from the same data set. The comparison is for the same ligand between OX1 and OX2. (D) Comparison of the same data normalized to the pEC50
of orexin-A in each batch. The values are equal to the logarithm of the fold difference in potency (pEC50-orexin-A  pEC50-ligand = log(EC50-ligand/EC50-orexin-A)). The ﬁrst
comparison (‘‘’’) is for the other agonists to orexin-A (=0), separately for each receptor subtype. The second comparison (‘‘’’) is similarly between orexin-B and A11,DL15-
orexin-B. The third comparison (‘‘’’) is for the same ligand (orexin-B or A11,DL15-orexin-B) between OX1 and OX2.
Fig. 4. Responses to the activation of receptors of the ﬁrst round and second round of mutagenesis. (A) The averaged ‘‘raw’’ data. The comparison is for orexin-A between
different constructs. (B) The same data were normalized to the orexin-A in each batch of cells (as in Fig. 3D. The ﬁrst comparison (‘‘’’) is for the other agonists to orexin-A (=0),
separately for each receptor subtype. The second comparison (‘‘’’) is similarly between orexin-B and A11,DL15-orexin-B.
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Ch1 and Ch6, i.e. the receptors with the largest part from OX2
but with either N- or C-terminal quarter from OX1 (Fig. 2), were
actually even more like the ‘‘classical’’ OX2, i.e. with higher potency
of orexin-B and A11,DL15-orexin-B (see e.g. [2]), than OX2 itself
(Fig. 4). Although A11,DL15-orexin-B is close to orexin-B, it does
not show completely similar requirements of receptor determi-nants for receptor binding/activation. For instance, orexin-B shows
the same relative potency for Ch2 as for OX1, whereas the potency
of A11,DL15-orexin-B for Ch2 is somewhat elevated. Insertion of the
2nd quarter (TM2–TM4) of the OX2 receptor in the OX1 receptor
(Ch7) produces a receptor that is indistinguishable from OX2 with
respect to orexin-B, but with a reduced potency of A11,DL15-orexin-
B. In contrast, Ch8 is rather half-way between OX1 and OX2 with
Fig. 5. Amino acid diversity between OX1 and OX2 in the region determining most of the peptide agonist selectivity, between the cut-points 1 and 2 (see Fig. 1). The alignment
was performed with ClustalW (http://www.align.genome.jp/) and the scaling is based on that of given by this program. Strongest diversity is indicated with 1, while some
similarity (‘‘:’’ and ‘‘.’’ of ClustalW) gives 0.5. Printed on the bars, the sequences of OX1 (above) and OX2 (below) in this region.
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above). In conclusion, it seems that although TM2–TM4 represents
the most important part the receptor, the entire receptor makes an
entity, for instance so that the more N- and C-terminal parts have
adapted to an interaction with each other. Secondly, orexin-B vari-
ants are, somewhat unexpectedly, not equal in their binding/acti-
vation properties. Thirdly, it seems that the receptor is prone to
‘‘relaxing’’ towards the agonist non-selective conformation (or
slightly higher potency of orexin-B than orexin-A) as it is easier
to get a more OX2-like proﬁle than an OX1-like proﬁle.
If the TM2–TM4 area is the most important part for agonist pep-
tide distinction, what determinants then within this domain could
be important? Even when the 2nd intracellular loop is eliminated
as unlikely for the agonist binding, this domain contains the 2nd
extracellular loop and (at least parts of) the transmembrane helices
2, 3 and 4, all of which may affect the agonist binding, based on the
very little information there is available on the peptide binding to
peptide receptors. Analysis of the amino acid sequence variation in
this region does not reveal any obvious site; the sequences are
mostly identical and the diversity is rather evenly distributed along
the amino acid chain except for some concentration in the TM4
(Fig. 5). For further analysis of receptor determinants, modeling
of the receptor structure would probably be necessary. However,
this is not a trivial task, despite development of the algorithms
and the four already available crystal structures, as also illustrated
by the results of a recent study on orexin receptors [16]. Receptor
mutagenesis is also not a straight-forward approach, as the correct
folding may be compromised in the mutant receptors. To compen-
sate for this, we used functional Ca2+ responses in intact cells,
which should take place through the properly folded receptors
only. Some of the constructs, in particular Ch4 and Ch8, showed
generally weak expression, but even these constructs produced
functional responses. Another parameter of interest would be the
binding afﬁnity. Unfortunately, the only commercially available
radioligands, 125I-orexin-A and -B, are not very useful because of
assay problems such as very high glass-ﬁber binding and the gen-
eral complications associated with agonist binding to (intact) cells,
including the fact that this also is affected by the receptor–G-pro-
tein-interaction [17]. We actively work to develop a binding assay
devoid of or less-affected by these problems.
In conclusion, the results of the chimaeric mutagenesis studies
suggest that the most signiﬁcant distinction between orexin pep-
tides occurs in the region from the C-terminal end of TM2 to the
C-terminal end of TM4 of the receptor. This explains most, but
not all the selectivity, and it seems that the receptor subtypes
may have evolved to stabilize their internal structures.Acknowledgements
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